Loading...
Market
What will be the next major milestone for Ascendis Pharma's TransCon CNP by December 31, 2024?
2
Resolution / Starting Odds
FDA Approval • 25%
EMA Approval • 25%
Phase 4 Trial Initiation • 25%
Other • 25%
Ascendis Pharma's official announcements or press releases
Story
Ascendis Pharma's TransCon CNP Achieves Primary Objective in ApproaCH Trial, Stock Surges 19.9%
Sep 16, 2024, 12:02 PM
Ascendis Pharma (ASND) announced that its pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) achieved its primary objective, demonstrating a superior annual growth velocity (AGV) compared to placebo. The trial showed a least squares mean treatment difference of 1.49 cm/year at Week 52, with children aged 5-11 years showing a change from baseline AGV superior to placebo with a least squares mean treatment difference of 1.78 cm/year at Week 52. Following the announcement, Ascendis Pharma's stock surged by 19.9% in pre-market trading. This development poses a competitive challenge to Biomarin's Voxzogo, which was previously considered superior. Ascendis Pharma's stock was up +17% in pre-market trading, while Biomarin's stock dropped by 15%. The trial was double-blind and placebo-controlled.
View original story
Similar markets
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
No acquisition • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Phase 3 trial initiation • 25%
FDA Breakthrough Therapy designation • 25%
Partnership announcement • 25%
No major milestone • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%